Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor

Ca2+ overload in myocardial cells is responsible for arrhythmia. Sodium–calcium exchanger (NCX) inhibitors are more effective than sodium–hydrogen exchanger (NHE) inhibitors with regard to modulation of Ca2+ overload, because NCX inhibitors can directly inhibit the influx of Ca2+ into cells. NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion. We have designed and synthesized a series of N-(2-aminopyridin-4-ylmethyl)nicotinamide derivatives, based on compound 5. We have discovered a novel NCX inhibitor (23h) with an IC50 value of 0.12 μM against reverse NCX. The inhibitory activities of our NCX inhibitors against cytochrome P450 were also evaluated. The effects on heart failure and the pharmacokinetic profile of compound 23h are discussed.

A series of 2-aminopyridine derivatives were prepared and evaluated for their inhibitory activities against the reverse and forward modes of the sodium–calcium exchanger (NCX). The structure–activity relationships of these compounds and their inhibitory activities against NCX are discussed. N-[(2-Aminopyridin-4-yl)methyl]-6-{4-[(3-fluorobenzyl)oxy]phenoxy}nicotinamide was evaluated for its effect in a heart failure model.Figure optionsDownload as PowerPoint slide